Additional European Equity News

Britvic (BVIC LN) - Board says the second proposal from the Carlsberg Group (CARLB DC) has been unanimously rejected, proposed was at GBP 12.50/shr; proposal was rejected on 17th June, received on the 11th. Proposal significantly undervalued the Co. and current/future prospects. (Newswires) Co. closed at 10.23/shr

Covestro (1COV GY) - CEO Steilemann, on the potential deal with Adnoc, says "the purchase price alone is not decisive" adding that talks are done in the interest of society, shareholders and employees. Says the talks are "objective and open-ended". (WiWo)

Covivo (COV FP) - Co. and Accorinvest signa  MoU with a view of consolidating their hotel property and operating companies; agreed value transferred to Accorinvest is EUR 208mln. Transaction expected to close in Q4'24. (Newswires) 

Compass Group (CPG LN) - Non-discretionary agreement with JPM to enable purchase of up to market equivalent of USD 250mln. (Newswires) 

Informa (INF LN) - Trading Update: Reiterates FY guidance; on track to deliver at upper end of 2024 guidance range. (Newswires) 

Geberit (GEBN SW) - End of share buyback programme 2022-24 and launch of new buyback programme. (Newswires) 

Santander (SAN SM) - Co. nears EU-wide deal with Amazon (AMZN) for consumer finance partnership, via Bloomberg. (Bloomberg)

STMicrolectronics (STMPA FP) - Announced the completion of its 2021 share buyback programmes, and launched a new USD 1.1bln share buyback plan for 2024. (Newswires) 

Wendel (WEN FP) - Supports Scalian to acquire Mannarino Systems & Software. (Newswires) 

UK Retail Sales MM (May) 2.9% vs. Exp. 1.5% (Prev. -2.3%, Rev. -1.8%); clothing retailers rebounded in May following poor weather in April. (Newswires) 

UniCredit (UCG IM) - Bought 2.67% of share capital for EUR 1.59bln as part of buyback tranche. (Newswires) 

Zealand Pharma (ZEAL DC) - Positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide; Results provide robust support of the potential of petrelintide as an effective alternative to GLP-1RA-based therapies for weight management. Anticipates initiation of a Phase 2b clinical trial in H2 2024. (Zealand Pharma)

ABB (ABBN SW) downgraded to Sell from Hold at Deutsche Bank

B&M European (BME LN) downgraded to Underweight from Equal Weight at Morgan Stanley 

21 Jun 2024 - 07:10- EquitiesResearch Sheet- Source: Newsquawk